healthcare

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a Carmiel, Israel-based biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, secured securities purchase agreements, or the Purchase Agreements, to raise $43.7m through a private equity investment (PIPE).